6 news items
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
ALLO
13 May 24
to register. Upon registering for the conference call, you will receive a personal PIN to access
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
ALLO
6 May 24
to register. Upon registering for the conference call, you will receive a personal PIN to access the call
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
ALLO
26 Apr 24
to increase access for diverse patient populations. Additionally, the grant will support translational and clinical analyses to inform a recommended Phase 2
Allogene Therapeutics And Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement To Support Advancement Of Next-Generation Allogeneic CAR T Platform In Autoimmune Disease
ALLO
12 Mar 24
differentiation key for future success. This agreement provides us access to Arbor's proprietary gene-editing technology and know-how, allowing us
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
ALLO
12 Mar 24
differentiation key for future success. This agreement provides us access to Arbor's proprietary gene-editing technology and know-how, allowing us to develop what
3vxwzpsd6da9d21hj43ya7qcievxvlh1methc6sd6aj tbz9k
ALLO
5 Mar 24
will receive a personal PIN to access the call. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South
- Prev
- 1
- Next